


Shyam Patel
505 posts

@ShyamLPatel
@the_BMC ICU/ED PharmD, BCCCP | @BMCPharmRes and @UConnHealthRx alum | @UConnPharmacy grad | he/him/his








...🧵This is a thread about 8.4% sodium bicarbonate (aka bicarb amp) in critical care. This the first part in a series of three about sodium bicarbonate 🧂in critical care: 🧐I will get in deep to complexities, benefits, risks and clinical implications of this (overused) drug.











A summary of "Andexanet for Factor Xa Inhibitor–Associated Acute Intracerebral Hemorrhage" (ANNEXA-I) by Stuart Connolly et al NEJM: 1. 🔬 Study Purpose: Evaluated the effectiveness of andexanet alfa in controlling hematoma expansion in patients with intracerebral hemorrhage on factor Xa inhibitors. 2. 🧪 Methods: 530 patients were randomly assigned to receive either andexanet or usual care, with primary endpoints being hemostatic efficacy and safety endpoints like thrombotic events and death. 3. 📊 Results: Andexanet achieved better control of hematoma expansion (67.0%) compared to usual care (53.1%), but it increased thrombotic events (10.3% vs. 5.6%). 4. 💉 Treatment Efficacy: The median reduction in anti–factor Xa activity was significantly higher with andexanet (94.5%) compared to usual care (26.9%). 5. ⚠️ Safety Concerns: While effective in controlling hematoma expansion, andexanet was associated with a higher risk of thrombotic events, including ischemic stroke. #CODE #ICH nejm.org/doi/full/10.10…










